Profiles of substance use disorders in patients of therapeutic communities: Link to social, medical and psychiatric characteristics

Drug and Alcohol Dependence

Volumn 149, Issue , 2015, Pages 31-39

  Fernández Calderón, David ^a   Fernández, Fermín ^b,c   Ruiz Curado, Sofía ^d   Verdejo García, Antonio ^e,f   Lozano, Óscar M ^c,e  

^a Agency of Social Services and Dependence of Ansalusia   (Spain)

^b Agency of Social Services and Dependence of Andalusia   (Spain)

^c UNIVERSITY OF HUELVA   (Spain)

^d UNIVERSIDAD PABLO DE OLAVIDE   (Spain)

^e UNIVERSITY OF GRANADA   (Spain)

^f MONASH UNIVERSITY   (Australia)

Author keywords

Comorbidity; Latent class analysis; Multiple substance use disorders

Indexed keywords

BENZODIAZEPINE DERIVATIVE; CANNABIS; COCAINE; OPIATE;

ADJUSTMENT DISORDER; ADULT; ALCOHOLISM; ANXIETY DISORDER; ARTICLE; BENZODIAZEPINE DEPENDENCE; CANNABIS ADDICTION; COCAINE DEPENDENCE; COGNITIVE DEFECT; COMORBIDITY; CONTROLLED STUDY; CRIMINAL BEHAVIOR; DEMOGRAPHY; DISSOCIATIVE DISORDER; DIVORCED PERSON; EATING DISORDER; EDUCATIONAL STATUS; EMPLOYMENT STATUS; FACTITIOUS DISEASE; FEMALE; GENDER DYSPHORIA; HEPATITIS B; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN IMMUNODEFICIENCY VIRUS PREVALENCE; IMPULSE CONTROL DISORDER; IMPULSIVENESS; INFECTION; MAJOR CLINICAL STUDY; MALE; MARRIED PERSON; MENTAL DISEASE; MOOD DISORDER; MULTIPLE DRUG ABUSE; MULTIPLE SUBSTANCE USE DISORDER; OBSERVATIONAL STUDY; OPIATE ADDICTION; PREVALENCE; PRIORITY JOURNAL; PSYCHOSIS; SCHIZOPHRENIA; SLEEP DISORDER; SOCIAL ASPECT; SOMATOFORM DISORDER; SPAIN; SUBSTANCE ABUSE; THERAPEUTIC COMMUNITY; TREATMENT OUTCOME; UNEMPLOYMENT; COMPLICATION; DISEASES; EPIDEMIOLOGY; MENTAL DISORDERS; PSYCHOLOGY; SOCIOECONOMICS; SUBSTANCE-RELATED DISORDERS;

ADULT; ANXIETY DISORDERS; COGNITION DISORDERS; COMORBIDITY; DISEASE; FEMALE; HUMANS; IMPULSIVE BEHAVIOR; MALE; MENTAL DISORDERS; PREVALENCE; PSYCHOTIC DISORDERS; SOCIOECONOMIC FACTORS; SPAIN; SUBSTANCE-RELATED DISORDERS; THERAPEUTIC COMMUNITY; TREATMENT OUTCOME;

EID: 84926150730     PISSN: 03768716     EISSN: 18790046     Source Type: Journal    
DOI: 10.1016/j.drugalcdep.2015.01.013     Document Type: Article

References (55)

1. Abe C., Mon A., Durazzo T.C., Pennington D.L., Schmidt T.P., Meyerhoff D.J. Polysubstance and alcohol dependence: unique abnormalities of magnetic resonance-derived brain metabolite levels. Drug Alcohol Depend. 2013, 130:30-37. 10.1016/j.drugalcdep.2012.10.004.
2. Agencia de Servicios Sociales y Dependencia de Andalucía (ASSDA).Junta de Andalucía SIPASDA. Sistema de Información del Plan Andaluz sobre Drogas y Adicciones 2014, Available at:, (accessed 07.04.13). https://sipasda.info/.
3. Agrawal A., Lynskey M.T., Madden P.F., Bucholz K.K., Heath A.C. A latent class analysis of illicit drug abuse/dependence: results from the National Epidemiological Survey on Alcohol and Related Conditions. Addiction 2007, 102:94-104. 10.1111/j.1360-0443.2006.01630.x.
4. American Psychiatric Association Breviario DSM IV. Criterios Diagnósticos 1995, Masson, Barcelona.
5. Arenas F., del Valle M., López R., Martín J., Tirado P. Programa de intervención en comunidad terapéutica en Andalucía. Consejería de Asuntos Sociales 2003, Junta de Andalucía, Sevilla.
6. Beswick T., Best D., Rees S., Coomber R., Gossop M., Strang J. Multiple drug use: patterns and practices of heroin and crack use in a population of opiate addicts in treatment. Drug Alcohol Rev. 2001, 20:201-204. 10.1080/09595230120058588.
7. Bornovalova M.A., Daughters S.B., Lejuez C.W. Motivations for sexual risk behavior across commercial and casual partners among male urban drug users: contextual features and clinical correlates. Behav. Modif. 2010, 34:219-246. 10.1177/0145445510364414.
8. Brands B., Blake J., Marsh D.C., Sproule B., Jeyapalan R., Li S. The impact of benzodiazepine use on methadone maintenance treatment outcomes. J. Addict. Dis. 2008, 27:37-48. 10.1080/10550880802122620.
9. Carrière M., Rosenberg A.R., Conti F., Chouzenoux S., Terris B., Sogni P., Soubrane O., Calmus Y., Podevin P. Low density lipoprotein receptor transcripts correlates with liver hepatitis C virus RNA in patients with alcohol consumption. J. Viral Hepat. 2006, 13:633-642. 10.1111/j.1365-2893.2006.00737.x.
10. Caton C.L.M., Drake R.E., Hasin D.S., Dominguez B., Shrout P.E., Samet S., Schanzer B., Schanzer W.B. Differences between early-phase primary psychotic disorders with concurrent substance use and substance-induced psychoses. Arch. Gen. Psychiatry 2005, 62:137-145. 10.1001/archpsyc.62.2.137.
11. Chen K.W., Banducci A.N., Guller L., Macatee R.J., Lavelle A., Daughters S.B., Lejuez C.W. An examination of psychiatric comorbidities as a function of gender and substance type within an inpatient substance use treatment program. Drug Alcohol Depend. 2011, 118:92-99. 10.1016/j.drugalcdep.2011.03.003.
12. Conway K.P., Kane R.J., Ball S.a., Poling J.C., Rounsaville B.J. Personality, substance of choice, and polysubstance involvement among substance dependent patients. Drug Alcohol Depend. 2003, 71:65-75. 10.1016/S0376-8716(03)00068-1.
13. De Leon G. The Therapeutic Community: Theory, Model, and Method 2000, Springer, New York.
14. Dutra L., Stathopoulou G., Basden S.L., Leyro T.M., Powers M.B., Otto M.W. A meta-analytic review of psychosocial interventions for substance use disorders. Am. J. Psychiatry 2008, 165:179-187. 10.1176/appi.ajp.2007.06111851.
15. Eiroa-Orosa F., Haasen C., Verthein U., Dilg C., Schafer I., Reimer J. Benzodiazepine use among patients in heroin-assisted vs. methadone maintenance treatment: findings of the German randomized controlled trial. Drug Alcohol Depend. 2010, 112:226-233. 10.1016/j.drugalcdep.2010.06.013.
16. European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) Treatment Demand Indicator Standard Protocol (TDI) 2.0 2000, Publications Office of the European Union, Luxembourg, Available at:, (accessed 21.03.14). http://www.emcdda.europa.eu/html.cfm/index65315EN.html.
17. European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) Polydrug Use: Patterns and Responses 2009, Publications Office of the European Union, Luxembourg, Available at:, (accessed 21.03.14). http://www.emcdda.europa.eu/publications/selected-issues/polydrug-use;TDSI09002ENC.
18. European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) EMCDDA, 2013-15 Strategy and Work Programme 2012, Publications Office of the European Union, Luxembourg, TDAR12001ENN. Available at: http://www.emcdda.europa.eu/html.cfm/index188832EN.html (accessed 21.03.14).
19. European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) European Drug Report 2013: Trends and Developments 2013, Publications Office of the European Union, Luxembourg, TDAT13001ENN. Available at: http://www.emcdda.europa.eu/html.cfm/index31211EN.html (accessed 21.03.14).
20. European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) Therapeutics Communities for Treating Addiction in Europe 2014, Publications Office of the European Union, Luxembourg, Available at:, (accessed 21.03.14). http://www.emcdda.europa.eu/attachements.cfm/att_226003_EN_TDXD14015ENN_final.pdf.
21. Fernandez-Serrano M.J., Lozano O., Perez-Garcia M., Verdejo-Garcia A. Impact of severity of drug use on discrete emotions recognition in polysubstance abusers. Drug Alcohol Depend. 2010, 109:57-64. 10.1016/j.drugalcdep.2009.12.007.
22. Geissler M., Gesien A., Wands J.R. Inhibitory effects of chronic ethanol consumption on cellular immune responses to hepatitis C virus core protein are reversed by genetic immunizations augmented with cytokine-expressing plasmids. J. Immunol. 1997, 159:5107-5113.
23. Hakansson A., Schlyter F., Berglund M. Associations between polysubstance use and psychiatric problems in a criminal justice population in Sweden. Drug Alcohol Depend. 2011, 118:5-11. 10.1016/j.drugalcdep.2011.02.014.
24. Harrell P.T., Mancha B.E., Petras H., Trenz R.C., Latimer W.W. Latent classes of heroin and cocaine users predict unique HIV/HCV risk factors. Drug Alcohol Depend. 2012, 122:220-227.
25. Hartzler B., Donovan D.M., Huang Z. Comparison of opiate-primary treatment seekers with and without alcohol use disorder. J. Subst. Abuse Treat. 2010, 39:114-123. 10.1016/j.jsat.2010.05.008.
26. Hjorthøj C., Fohlmann A., Nordentoft M. Treatment of cannabis use disorders in people with schizophrenia spectrum disorders - a systematic review. Addict. Behav. 2009, 34:520-525. 10.1016/j.addbeh.2009.02.001.
27. Jones J.D., Mogali S., Comer S.D. Polydrug abuse: a review of opioid and benzodiazepine combination use. Drug Alcohol Depend. 2012, 125:8-18. 10.1016/j.drugalcdep.2012.07.004.
28. Kelly T.M., Daley D.C., Douaihy A.B. Treatment of substance abusing patients with comorbid psychiatric disorders. Addict. Behav. 2012, 37:11-24. 10.1016/j.addbeh.2011.09.010.
29. Kessler R.C., Berglund P., Demler O., Jin R., Merikangas K.R., Walters E.E. Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the national comorbidity survey replication. Arch. Gen. Psychiatry 2005, 62:768. 10.1001/archpsyc.62.6.593.
30. Martins S.S., Gorelick D.A. Conditional substance abuse and dependence by diagnosis of mood or anxiety disorder or schizophrenia in the U.S. population. Drug Alcohol Depend. 2011, 119:28-36. 10.1016/j.drugalcdep.2011.05.010.
31. Meiler C., Muhlbauer M., Johann M., Hartmann A., Schnabl B., Wodarz N., Schmitz G., Scholmerich J., Hellerbrand C. Different effects of a CD14 gene polymorphism on disease outcome in patients with alcoholic liver disease and chronic hepatitis C infection. World J. Gastroenterol. 2005, 11:6031-6037.
32. Mortlock K.S., Deane F.P., Crowe T.P. Screening for mental disorder comorbidity in Australian alcohol and other drug residential treatment settings. J. Subst. Abuse Treat. 2011, 40:397-404. 10.1016/j.jsat.2011.01.002.
33. Muthen B. Should substance use disorders be considered as categorical or dimensional?. Addiction 2006, 101(Suppl. 1):6-16. 10.1111/j.1360-0443.2006.01583.x.
34. Perez de los Cobos J., Duro P., Trujols J., Tejero A., Batlle F., Ribalta E., Casas M. Methadone tapering plus amantadine to detoxify heroin-dependent inpatients with or without an active cocaine use disorder: two randomised controlled trials. Drug Alcohol Depend. 2001, 63:187-195.
35. Reboussin B.A., Song E., Shrestha A., Lohman K.K., Wolfson M. A latent class analysis of underage problem drinking: evidence from a community sample of 16-20 year olds. Drug Alcohol Depend. 2006, 83:199-209.
36. Reissner V., Kokkevi a., Schifano F., Room R., Storbjork J., Stohler R., DiFuria L., Rehm J., Geyer M., Hoscher F., Scherbaum N. Differences in drug consumption, comorbidity and health service use of opioid addicts across six European urban regions (TREAT-project). Eur. Psychiatry 2012, 27:455-462. 10.1016/j.eurpsy.2010.10.001.
37. Reske M., Paulus M.P. Predicting treatment outcome in stimulant dependence. Ann. N. Y. Acad. Sci. 2008, 1141:270-283. 10.1196/annals.1441.011.
38. Ross J., Teesson M., Darke S., Lynskey M., Ali R., Ritter A., Cooke R. The characteristics of heroin users entering treatment: findings from the Australian treatment outcome study (ATOS). Drug Alcohol Rev. 2005, 24:411-418. 10.1080/09595230500286039.
39. Schwartz B., Wetzler S., Swanson A., Sung S.C. Subtyping of substance use disorders in a high-risk welfare-to-work sample: a latent class analysis. J. Subst. Abuse Treat. 2010, 38:366-374. 10.1016/j.jsat.2010.03.001.
40. Shand F.L., Degenhardt L., Slade T., Nelson E.C. Sex differences amongst dependent heroin users: histories, clinical characteristics and predictors of other substance dependence. Addict. Behav. 2011, 36:27-36. 10.1016/j.addbeh.2010.08.008.
41. Siu L., Foont J., Wands J.R. Hepatitis C virus and alcohol. Semin. Liver Dis. 2009, 29:188-199. 10.1055/s-0029-1214374.
42. Stein J.A., Andersen R.M., Robertson M., Gelberg L. Impact of hepatitis B and C infection on health services utilization in homeless adults: a test of the Gelberg-Andersen Behavioral Model for Vulnerable Populations. Health Psychol. 2012, 31:20-30.
43. Szerman N., Gonzalez C.B., Sancho A.M., Grigioni G., Carduza F., Vaudagna S.R. Effect of the addition of conventional additives and whey proteins concentrates on technological parameters, physicochemical properties, microstructure and sensory attributes of sous vide cooked beef muscles. Meat Sci. 2012, 90:701-710. 10.1016/j.meatsci.2011.08.013.
44. Tortajada S., Jesus Herrero M., Domingo-Salvany A., Molist G., Barrio G., de la Fuente L., Teresa Brugal M. Psychiatric morbidity among cocaine and heroin users in the community. Adicciones 2012, 24:201-210. Grp Invest ITINERE.
45. Tortu S., McMahon J.M., Pouget E.R., Hamid R. Sharing of noninjection drug-use implements as a risk factor for hepatitis C. Subst. Use Misuse 2004, 39:211-224.
46. Trillo A.D., Merchant R.C., Baird J.R., Ladd G.T., Liu T., Nirenberg T.D. Interrelationship of alcohol misuse, HIV sexual risk and HIV screening uptake among emergency department patients. BMC Emerg. Med. 2013, 30:13-19. 10.1186/1471-227X-13-9.
47. Uebersax J. Latent class analysis of substance use patterns. Advances in Data Analysis for Prevention Intervention Research. NIDA Research Monograph, no. 142 1994, National Institute on Drug Abuse, Rockville, MD. L.M. Collins, L.A. Seitz (Eds.).
48. Van Os J., Bak M., Hanssen M., Bijl R.V., de Graaf R., Verdoux H. Cannabis use and psychosis: a longitudinal population-based study. Am. J. Epidemiol. 2002, 156:319-327.
49. Vanyukov M.M., Kirisci L., Tarter R.E., Simkevitz H.F., Kirillova G.P., Maher B.S., Clark D.B. Liability to substance use disorders: 2. a measurement approach. Neurosci. Biobehav. Rev. 2003, 27:517-526.
50. Verdejo-García A., Orozco-Gimenez C., Lopez-Torrecillas F., Puente A.E., Sedo M.A., Perez-Garcia M. Relationship between oral trail making (OTM) and trail making test (TMT) in a substance abuse sample. Arch. Clin. Neuropsychol. 2002, 17:814-819.
51. Verdejo-García A., Lopez-Torrecillas F., Gimenez C.O., Perez-Garcia M. Clinical implications and methodological challenges in the study of the neuropsychological correlates of cannabis, stimulant, and opioid abuse. Neuropsychol. Rev. 2004, 14:1-41.
52. Williamson A., Darke S., Ross J., Teesson M. The effect of persistence of cocaine use on 12-month outcomes for the treatment of heroin dependence. Drug Alcohol Depend. 2006, 81:293-300. 10.1016/j.drugalcdep.2005.08.010.
53. Wu L.T., Woody G.E., Yang C., Blazer D.G. Subtypes of nonmedical opioid users: results from the national epidemiologic survey on alcohol and related conditions. Drug Alcohol Depend. 2010, 112:69-80. 10.1016/j.drugalcdep.2010.05.013.
54. Wu L.T., Woody G.E., Yang C., Pan J.J., Blazer D.G. Abuse and dependence on prescription opioids in adults: a mixture categorical and dimensional approach to diagnostic classification. Psychol. Med. 2011, 41:653-664. 10.1017/S0033291710000954.
55. Zammit S., Allebeck P., Andreasson S., Lundberg I., Lewis G. Self reported cannabis use as a risk factor for schizophrenia in Swedish conscripts of 1969: historical cohort study. BMJ 2002, 325:1199.